A two-day life-science partnering and investment congress in Lyon, built around qualified one-to-one meetings that connect early to growth-stage biotech, medtech and digital health companies with investors, with AI and digital transformation running through the pharmatech track.
LSX World Congress Europe, branded LSX Europe, is a life-science partnering, strategy and investment congress organised by Informa Connect. It is built around qualified one-to-one partnering meetings that connect early to growth-stage companies in biotech, medtech, pharmatech and digital health with investors and strategic partners. The event runs a city-rotating European format, moving from London to Lisbon in 2026 and to Lyon for 2027, where the main congress is scheduled for 7 to 8 April with a company-only pre-day on 6 April. The organiser reports more than 1,500 senior attendees, 500 investors and 4,000 partnering meetings.
LSX exists for dealmaking and fundraising rather than continuing education. Its centre of gravity is the partnering platform, where founders and business development leads meet investors in scheduled one-to-one sessions, supported by thought-leadership content, panels and pitch opportunities. For a digital health or medtech company, the value is investor access and partnership conversations at the seed to Series B stage, which makes it a strategy and capital event rather than a product showcase.
The programme is organised into leader tracks:
Alongside the partnering platform, LSX runs expert insight sessions with interactive question and answer formats, panel discussions, real-world case studies, partnering booths, innovation showcases and company pitch sessions. A pre-day forum the day before the main congress is restricted to life-science companies.
The event is attended at senior level across the sector. Organisations represented at the 2026 edition included Jazz Pharmaceuticals, Baxter, Elekta and Servier, alongside investors such as Novo Holdings, Gilde Healthcare and Forbion. A 2027 speaker roster is not yet published.
Primarily a partnering event. The content programme is real, but the core of LSX is the qualified one-to-one partnering platform and investor access, which is what most attendees come for.
Digital health companies are a named target segment alongside biotech, medtech and pharmatech, and AI and digital transformation are covered inside the Pharmatech Leaders track rather than on a standalone AI stage.
The 2027 edition moves to Lyon, France, a recognised European life-science cluster, with the specific venue to be confirmed by the organiser. The 2026 edition was held at the Lisbon Congress Centre.
LSX World Congress is organised by Informa Connect, part of Informa, building on the legacy LSX brand formerly known as Biotech and Money. Informa Connect also runs a US sibling event, LSX Congress USA.
LSX World Congress Europe is the partnering and investment counterpart to Europe's science conferences, a curated room of 500-plus investors where digital health and AI sit inside the pharmatech track rather than on a separate stage.
Registration is through the official website. LSX offers Premium, Standard content, Investor, Showcase and Press passes; the Investor pass is free for qualified investors subject to terms. Exact amounts are quoted through the registration process rather than published on a public price page.
In Lyon, France, with the venue to be confirmed. The main congress runs 7 to 8 April 2027, with a company-only pre-day on 6 April.
Yes. A dedicated Investor pass gives all-access partnering free to qualified investors, subject to the organiser's terms.
Scheduled one-to-one meetings with other attendees, arranged through the LSX partnering system, which is the core of the Premium and Investor passes.
| Official website | https://informaconnect.com/lsx-world-congress/ |
| Register | https://informaconnect.com/lsx-world-congress/purchase/select-package/ |
| Organiser | https://informaconnect.com/ |